Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by Wall Street Zen

Seres Therapeutics (NASDAQ:MCRB) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

MCRB has been the subject of a number of other research reports. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. HC Wainwright started coverage on shares of Seres Therapeutics in a report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Seres Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Stock Performance

Shares of MCRB opened at $4.87 on Friday. The stock has a market cap of $48.41 million, a P/E ratio of -2.00 and a beta of 0.20. Seres Therapeutics has a 1 year low of $4.59 and a 1 year high of $29.98. The stock’s 50-day moving average price is $6.18 and its two-hundred day moving average price is $8.40.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65. The company had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.18 million. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%. As a group, equities analysts forecast that Seres Therapeutics will post -4.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MCRB. Geode Capital Management LLC lifted its stake in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after acquiring an additional 1,160 shares in the last quarter. Invesco Ltd. grew its stake in shares of Seres Therapeutics by 37.5% during the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 3,918 shares in the last quarter. State Street Corp grew its stake in shares of Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 4,170 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Seres Therapeutics by 4.8% in the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 4,723 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 5,157 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.